Abstract

A lacrimal drug delivery device includes a reservoir configured to hold a drug. The reservoir is moveable between a relaxed state and an expanded state. A connector is fluidly coupled to the reservoir and a lumen is formed in the connector wherein the drug is configured to flow from the reservoir to a delivery site through the lumen. A hydrogel is within the lumen and configured to absorb the drug from the reservoir and deliver the drug from the lumen at the delivery site. The hydrogel includes a first section which absorbs the drug at a first rate of absorption. A delivery guide is detachably coupled to the reservoir to deliver the reservoir into a lacrimal sac of a patient.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups

Abstract

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A computer system for intra-ear sensing and stimulating receives, health data, from an earbud sensor. The system repeatedly calculates an exponential moving average (EMA) of a moving window for the received health data. The system compares each calculated exponential moving average with a lower threshold value and an upper threshold value. The upper threshold value and the lower threshold value are determined based, at least in part, upon a saturation level associated within an amplifier performing the adaptive gain control. When the calculated exponential moving average is larger than the upper threshold, the system decreases a gain associated with the amplifier. When the calculated exponential moving average is smaller than the lower threshold, the system increases a gain associated with the amplifier.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/369 - Electroencephalography [EEG]
• A61B 5/389 - Electromyography [EMG]
• A61B 5/398 - Electrooculography [EOG], e.g. detecting nystagmusElectroretinography [ERG]
• A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

Compositions comprising butyric acid and derivatives thereof for a method of treating intestinal disease. These compositions act to stabilize HIF through the inhibition of PHDs.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Abstract

The invention provides methods, systems, and compositions of preparing samples for nucleic amplification by application of surface acoustic waves (SAWs).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The system and methods of the present invention involve estimating model parameters for non-linear systems of Differential Equations (DEs). This includes receiving data from these systems and applying Weak-form Estimation of Nonlinear Dynamics methods to the data. These methods are robust to instances of large measurement noise. The system and methods also involve converting strong form representations of a model to weak forms, solving regression problems to perform parameter inference, and using Errors-In-Variables frameworks and iteratively reweighted least squares algorithms. The system and methods of the present invention can be applied to various models from different fields such as population biology, neuroscience, and biochemistry. The system and methods are highly robust and exhibit computational efficiency when used to estimate parameters in some common models including logistic growth, Lotka-Volterra, FitzHugh-Nagumo, Hindmarsh-Rose, a Protein Transduction Benchmark model and Kuramoto-Sivashinsky.

IPC Classes  ?

• G06N 5/04 - Inference or reasoning models
• G06F 17/13 - Differential equations

Abstract

Methods and systems for splitting one or more of water and carbon dioxide are disclosed. Exemplary methods can operate under substantially isothermal conditions. The methods can include use of a material including two or more spinel phases in a solid solution. The solid solution can include oxygen, aluminum, and one or more transition metals.

IPC Classes  ?

• C01B 3/06 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents
• B01J 8/00 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes
• B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
• C01B 32/40 - Carbon monoxide

Abstract

Noninvasive imaging plays an important role in determining the size of the transcatheter heart valve (THV) in preparation of a transcatheter aortic valve replacement (TAVR) procedure. The identification of the coronary cuspid landmarks or nadirs of each cusp plays a key role in determining the reference points for the two-dimensional (2D) images of the THV. Rather than using nadirs that are currently identified manually upon inspection of 2D computed tomography (CT) images, the methods and systems of the present disclosure utilizing structured 3D dataset of cusps to simultaneously determine the nadirs, which are especially beneficial, particularly when the sizes of cusps have significant difference (i.e., Type 1 aortic valve with two fused leaflets) or the aortic root has a bicuspid configuration rather than a tricuspid configuration.

IPC Classes  ?

• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61F 2/24 - Heart valves
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06T 7/174 - SegmentationEdge detection involving the use of two or more images
• G06T 15/08 - Volume rendering
• G06T 15/20 - Perspective computation

Abstract

The invention provides methods, systems, and compositions of preparing samples for nucleic amplification by application of surface acoustic waves (SAWs).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 1/28 - Preparing specimens for investigation

Abstract

Methods for the early detection of subjects at risk of developing rheumatoid arthritis, and subjects having early rheumatoid arthritis thus allowing for early intervention.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

In various implementations, string inverter circuit configurations are provided that allow for increased device lifetimes. In one implementation, for example, an inverter includes a pair of inverter input terminals. A ground-balancing converter module is coupled between the pair of inverter input terminals and ground. The ground is disposed between each of the pair of inverter input terminals. A plurality of converter modules is coupled to an output of the ground-balancing converter module, each of the plurality of converter modules providing an output ac phase of the inverter. In another implementation, a method of controlling an inverter is provided. The method includes controlling a voltage level of each terminal of the pair of inverter input terminals to have equal magnitudes and opposite polarities with respect to a ground voltage.

IPC Classes  ?

• H02M 1/12 - Arrangements for reducing harmonics from AC input or output
• H02M 7/49 - Combination of the output voltage waveforms of a plurality of converters

Abstract

Methods of treating idiopathic nephrotic syndrome in a subject involve reducing urinary and/or blood levels of CD93, reducing or inhibiting CD93-mediated podocyte activation. or reducing or inhibiting CD93 release from glomerular endothelial cells. The methods may include administration of a composition including at least one of an anti-CD93 antibody and an inhibitor of pi integrin.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

IPC Classes  ?

• C07K 14/74 - Major histocompatibility complex [MHC]
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 40/10 - Cellular immunotherapy characterised by the cell type used
• A61K 40/22 - Immunosuppressive or immunotolerising
• A61K 40/41 - Vertebrate antigens
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

Insulated assemblies, insulation units including an assembly, and methods of forming the assemblies and units are disclosed. Exemplary assemblies include a first pane of material, a second pane of material, and one or more monolithic insulating layers interposed between the first pane of material and the second pane of material. The insulating layer can exhibit a thermal conductivity less than 26 mW/(K·m).

IPC Classes  ?

• E06B 3/67 - Units comprising two or more parallel glass or like panes in spaced relationship, the panes being permanently secured together, e.g. along the edges characterised by additional arrangements or devices for heat or sound insulation
• E06B 3/673 - Assembling the units

Abstract

A cryocooling system includes a compressor, a refrigerator, and a controller, which is communicatively coupled to the compressor and the refrigerator. The compressor is configured to be driven at a drive frequency. The refrigerator is coupled to the compressor via a first fluid path and includes a cold heat exchanger, an output, a reservoir, and a flow resistor. The flow resistor controls fluid flow along a second fluid path between the output and the reservoir. The controller optimizes a rate of cooling of the cold heat exchanger by adjusting both a drive frequency of the compressor and a resistance of the flow resistor along the second fluid path.

IPC Classes  ?

• F25B 9/10 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point with several cooling stages
• F25B 9/14 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point characterised by the cycle used, e.g. Stirling cycle

Abstract

Embodiments of the present invention generally relate to monoclonal antibodies or polypeptides directed to bind to SEMA7A. In certain embodiments, these antibodies or polypeptides are of use to treat or reduce onset of health conditions. In certain embodiments, compositions and methods disclosed herein concern using SEMA7A monoclonal antibodies for diagnosis, prevention and/or treatment of cancers, cardiac conditions, and other health conditions. In certain embodiments, SEMA7A levels detected by the monoclonal antibodies disclosed herein can be used to project progression of a condition and course of intervention. In some embodiments, cancers can be targeted. In other embodiments, cancer stem cells can be targeted. In other embodiments, monoclonal antibodies can be used to treat cancers such as breast cancer and other cancers having SEMA7A expression or over-expression in a subject.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

This disclosure relates to modified receptors comprising a MyD88 domain, as well as cells comprising the same and methods of use thereof.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A power grid monitoring system includes one or more processors and a memory including instructions. The instructions, when executed by the one or more processors, cause the power grid monitoring system to monitor output measurements from a plurality of power generators and transmission lines connecting the plurality of power generators and loads, estimate an inertial momentum of the plurality of power generators, and predict an imminent transient behavior following a disturbance in at least one of the plurality of power generators, the transmission lines, or the loads based on the inertial momentum. The inertial momentum is based on an electromagnetic momentum in the transmission lines and mechanical and electrical momenta of the plurality of the power generators.

IPC Classes  ?

• H02J 13/00 - Circuit arrangements for providing remote indication of network conditions, e.g. an instantaneous record of the open or closed condition of each circuitbreaker in the networkCircuit arrangements for providing remote control of switching means in a power distribution network, e.g. switching in and out of current consumers by using a pulse code signal carried by the network
• G01R 31/42 - AC power supplies
• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks

Abstract

A novel combinatorial and high-throughput platform that enables rapid screening of complex and heterogeneous copolymer brushes as enzyme immobilization supports named Combinatorial High-throughput Enzyme Support Screening (CHESS). Using a 384 well-plate format, we synthesized arrays of three-component polymer brushes in the microwells using photo-activated surface-initiated polymerization, and immobilized enzymes in situ. The utility of CHESS to identify optimal immobilization supports under thermally and chemically denaturing conditions was demonstrated using Bacillus subtilis Lipase A (LipA). The identification of supports with optimal compositions was validated by immobilizing LipA on polymer-brush modified biocatalyst particles. We further demonstrated that CHESS could be used to predict the optimal composition of polymer brushes a priori for the previously unexplored enzyme, alkaline phosphatase (AlkP). Our findings demonstrate that CHESS represents a predictable and reliable platform for dramatically accelerating the search of chemical compositions for immobilization supports and further facilitate the discovery of biocompatible and stabilizing materials.

IPC Classes  ?

• G01N 33/44 - ResinsPlasticsRubberLeather
• C12N 11/098 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer formed in the presence of the enzymes or microbial cells
• C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
• C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase
• C12Q 1/46 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase involving cholinesterase
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/527 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving lyase
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

Disclosed herein are method and compounds useful in the analysis, diagnosis, and treatment of high grade serous ovarian carcinoma (HGSOC). Also disclosed are methods, compounds, and compositions useful in regulating Chromobox 2 (CBX2) expression and therapies for stemness, anoikis escape, HGSOC dissemination, and HGSOC chemoresistance. Applicants have identified CBX2 expression as being significantly elevated in HGSOC cells and tissues compared to benign counterparts. Also disclosed is elevated CBX2 expression in HGSOC cell lines, as well as elevated CBX2 expression in cells that are forced to grown in suspension. CBX2 expression can be used to identify subjects for treatment with therapies specifically directed to cancers characterized by CBX2 upregulation.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed are sensors and related methods for measuring enzyme activity in a measurement environment and for quantifying enzyme and/or microbe concentrations in the measurement environment. An enzyme activity sensor includes a degradable conductive trace and a biodegradable target configured to enable the conductive trace, in an initial state, to conduct electrical current between first and second terminal ends via conductive particles. The conductive trace is configured to degrade over time as a result of enzymatic activity that degrades the biodegradable target when the sensor is placed in a measurement environment, the enzymatic activity thereby increasing resistance between the first and second terminal ends.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

Abstract

An apparatus and method of crimping at least one stent to a predetermined size. The crimping apparatus may comprise at least one handle, such that at least one user may apply a force to the handle to crimp the perimeter of a stent. Additionally, the crimping apparatus may comprise a safety system configured to inhibit further crimping past a predetermined size. Accordingly, the safety system may comprise at least one stopper, such that once the at least one user selected a predetermined size, via a dial of the safety system, at least one crimping member of the crimping apparatus is prevented from movement further than the predetermined size. Furthermore, the crimping apparatus may comprise a chamfered opening, such that the integrity and structure of the s stent may be maintained during the crimping process.

IPC Classes  ?

• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts

Abstract

A vacuum-ultraviolet laser source for generating a frequency comb includes a laser operating at a high repetition rate for generating a regular train of pulses with high peak power. The train of pulses is separated into a frequency upconversion path and a fundamental frequency path. The frequency upconversion path generates an upconverted frequency at least three times the frequency of the train of pulses from the laser. The upconverted pulses are combined with the fundamental frequency pulses and a gas-filled waveguide effects a χ(3) upconversion process on the combination, generating a vacuum-ultraviolet spectral region frequency comb. This frequency comb is useful in generating a nuclear clock signal.

IPC Classes  ?

• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 3/109 - Frequency multiplication, e.g. harmonic generation
• H01S 3/063 - Waveguide lasers, e.g. laser amplifiers
• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks

Abstract

A quantum transducer includes a back gate having a doped semiconductor layer, a tunnel barrier located above the doped semiconductor layer, a quantum dot contacting a top surface of the tunnel barrier, a cap layer located above the tunnel barrier and covering the quantum dot, a surface acoustic wave (SAW) resonator located above the cap layer, a SAW transducer coupled to the SAW resonator, and a top gate located above the SAW resonator. The SAW resonator is mechanically coupled to the quantum dot. The depth and electrical conductivity of the doped semiconductor layer may be selected such that SAW attenuation is not the dominant contributor to the total phonon loss rate of the SAW resonator. The depth and electrical conductivity may also be selected such that the SAW transducer has a piezoelectric coupling constant of 0.055% or higher.

IPC Classes  ?

• H03H 9/02 - Networks comprising electromechanical or electro-acoustic elementsElectromechanical resonators Details
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• G02F 2/02 - Frequency-changing of light, e.g. by quantum counters
• H03H 9/25 - Constructional features of resonators using surface acoustic waves

Abstract

Provided are compounds and methods for the treatment of cancer.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 277/38 - Nitrogen atoms
• A61P 35/00 - Antineoplastic agents

Abstract

Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A01N 1/122 - Preservation or perfusion media
• A61K 31/60 - Salicylic acidDerivatives thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/12 - Cyclic peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

Metal chelates, methods of making the metal chelate, electrolyte formulations comprising metal chelates, and electrochemical devices for energy storage using or including at least one metal chelate are disclosed. The disclosure also relates to a method to provide a metal to an electrolyte in a flow battery to plate an electrode while the electrode is in the battery.

IPC Classes  ?

• H01M 8/1016 - Fuel cells with solid electrolytes characterised by the electrolyte material
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

Disclosed herein is a ceramic particle comprising a core substrate chosen from yttria-stabilized zirconia, partially stabilized zirconia, zirconium oxide, aluminum nitride, silicon nitride, silicon carbide, and cerium oxide, and a conformal coating of a sintering aid film having a thickness of less than three nanometers and covering the core substrate, and methods for producing the ceramic particle.

IPC Classes  ?

• C04B 35/488 - Composites
• C04B 35/624 - Sol-gel processing
• C04B 35/628 - Coating the powders
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1253 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides the electrolyte containing zirconium oxide

Abstract

A portable computed tomography (CT) system is provided herein. In an example, the portable CT system includes an O-shaped gantry defining an opening, an x-ray source operably coupled to the O-shaped gantry, a flat panel detector (FPD) coupled to the O-shaped gantry, and an antiscatter grid (ASG) operably coupled to a side of the FPD facing the opening of the O-shaped gantry. The FPD includes an x-ray absorbing sensor layer and a detector pixel array. The ASG includes a plurality of vertical walls defining open-ended channels and formed of a radiation-absorbing material. The open-ended channels are arranged in a geometric pattern pointed toward the x-ray source to receive x-rays in an x-ray emission path from the x-ray source.

IPC Classes  ?

• A61B 6/42 - Arrangements for detecting radiation specially adapted for radiation diagnosis
• A61B 6/40 - Arrangements for generating radiation specially adapted for radiation diagnosis
• G01T 1/20 - Measuring radiation intensity with scintillation detectors
• G01T 7/00 - Details of radiation-measuring instruments

Abstract

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents

Abstract

A gate driver is provided for switching high voltage switching circuitry. The gate driver includes a logic level gate driver configured to generate a first light and a second light, which is modulated, a power supply configured to convert the first light into power and supply the power, and an optical driver coupled to the power supply and configured to turn on an off the high voltage switching circuitry based on the second light.

IPC Classes  ?

• H03K 17/94 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the way in which the control signals are generated
• G01R 15/22 - Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks using light-emitting devices, e.g. LED, optocouplers
• H03K 17/16 - Modifications for eliminating interference voltages or currents

Goods & Services

Paper placards

Goods & Services

Weight management services, namely, providing weight loss and weight management health care services; consultation services in the field of weight management; health care services, namely, weight management care services; providing information in the fields of weight management, weight loss and the maintenance of weight loss; Health care services, namely, conducting weight management programs using web-enabled and printed materials and tools for providing improved weight management processes.

Goods & Services

Educational services, namely providing training and information, such as printed activities, videos and puppets, in the field of early language learning, through finger puppet interactions, for infants and families that optimizeschild development and early relational health.

Abstract

A load modulating loop combiner comprises a first coupler configured to couple a signal from an upper pathway to a lower pathway. A main amplifier is configured to receive the signal on the upper pathway. The main amplifier is connected to a first port of a three-port, non-isolating coupling structure. A first phase delay is configured to receive the signal that was coupled to the lower pathway. The first phase delay is connected to a summing junction. The summing junction is connected to a second port of the three-port, non-isolating coupling structure through a second phase delay. An output of the summing junction is connected to an input of an auxiliary amplifier. A third port on the three-port, non-isolating coupling structure is connected to an output of the auxiliary amplifier.

IPC Classes  ?

• H03F 1/02 - Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation
• H03F 1/32 - Modifications of amplifiers to reduce non-linear distortion
• H03F 1/56 - Modifications of input or output impedances, not otherwise provided for
• H03F 3/21 - Power amplifiers, e.g. Class B amplifiers, Class C amplifiers with semiconductor devices only

Abstract

An atomic vapor cell includes a bottom transparent substrate having a floor surface, a top transparent substrate having a ceiling surface, a frame, a bottom protective layer, a top protective layer, and an alkaline earth metal between the bottom and the top transparent substrates. The frame has a bottom surface bonded to the floor surface, a top surface opposite the bottom surface and bonded to the ceiling surface, a reservoir hole, an aperture, and a channel that connects the reservoir hole to the aperture. The top protective layer is on the ceiling surface and includes layer-regions that cover respective regions of the ceiling surface spanning across the reservoir hole and the aperture. The bottom protective layer is on the floor surface and includes a layer-region that covers a region of the floor surface that spans across the aperture. The alkaline earth metal is in the reservoir hole.

IPC Classes  ?

• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks

Abstract

A mechanical testing system for deformable samples, such as gels or tissues, is disclosed. The system includes a container for holding a liquid, and a floatable platform configured to float on the liquid. The platform includes attachments for connecting to a deformable sample and a force sensor assembly. The system allows for the application of unidirectional tension to the sample and the measurement of the resulting force by the force sensor assembly. The design of the system minimizes off-target forces and sample vibration, and allows for submerged testing and simultaneous imaging of the sample. The system is particularly suitable for testing small, soft materials such as extracellular matrix polymers.

IPC Classes  ?

• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces

Abstract

A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure: A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure: and methods of using these compounds to inhibit WEE1 kinase and treat cancer in a subject.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention is related to the generation and use of secreted fusogenic vesicles incorporating engineered viral glycoprotein, or engineered endogenous human fusiogenic proteins derived from human endogenous retroviruses proteins, such vesicles being generally referred to as “gectosomes.” The present invention is further related to the use of engineered gectosomes to deliver therapeutic molecules or antigens to cell and tissues in a targeted manner, as well as systems and methods for using gectosomes to screen for therapeutically relevant compounds or therapeutic antibodies.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/50 - Microcapsules
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present disclosure provides novel Vitamin D analogs, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly melanoma, ovarian, and breast cancers. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

IPC Classes  ?

• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

Patients with relapsing or refractory cancer have limited treatment options because the knowledge or presence of tumor-associated antigens is lacking. The proposed therapy mounts an antigen-independent anticancer response in a rapid, safe, and targeted manner due to its ability to stimulate innate immune cells in solid tumors, addressing a major, unmet major need in clinical oncology. A holistic system is disclosed capable of preparing and purifying cell samples for adoptive transfer into patients suffering from relapsing and refractory lymphomas and other solid cancers. An acoustofluidic device processes clinically relevant cell samples in a plug-and-play format, offering cell preparation speeds >100× faster than conventional CAR T-cell therapy.

IPC Classes  ?

• A61K 40/42 - Cancer antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to the use of one or more fructokinase (ketohexokinase) (KHK) inhibitors to both prevent and treat a wide variety of diseases including, but not limited to, alcohol craving, alcohol addiction, alcohol induced liver disease including fatty liver and cirrhosis.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 25/32 - Alcohol-abuse

Abstract

The present disclosure provides a securement assembly for an enteral access device or vesical access device (“access device”). The securement assembly includes a base and a lid. The base is generally configured to support an external port of the access device and the lid is pivotably coupled to the base. The base comprises a border rim and a central portion, wherein the border rim is configured to engage a skin surface of a patient around a stoma and the central portion is configured to engage the external port of the access device. The central portion may comprise opposing side arms defining an aperture through which a tube of the access device extends.

IPC Classes  ?

• A61J 15/00 - Feeding-tubes for therapeutic purposes

Abstract

Methods and systems for forming an object comprising sintered material are disclosed. An exemplary method includes producing a flash process using one or more flash source materials and forming a magnetic field, wherein the magnetic field and the flash process are used to form the object.

IPC Classes  ?

• B22F 3/105 - Sintering only by using electric current, laser radiation or plasma

Abstract

An imaging method includes: (I) simultaneously illuminating a scene with a first (second) diverging wave originating from a first (second) location and modulated with a first (second) shift-and-add-qualifying-code. A scatterer that scatters the first (second) diverging wave as a first (second) speckle. (II) Detecting, with a receiver, an interference signal, produced from interference between the speckle fields, and including a code temporally shifted with respect to the first SAA-code by a large-scale time-shift. (III) Circulantly correlating the interference signal with a reference SAA-code to generate a correlation signal. (IV) Determining the time-difference-of-arrival from the large-scale time-shift. (V) Determining a location of the scatterer by: determining, from the time-difference-of-arrival, a hyperbolic contour that locates the scatterer angularly; and determining, from one of (i) a small-scale time-shift of a peak of the correlation signal and (ii) a ranging delay, an elliptical contour that locates a range of the scatterer from the receiver.

IPC Classes  ?

• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging
• G01S 7/481 - Constructional features, e.g. arrangements of optical elements
• G01S 17/931 - Lidar systems, specially adapted for specific applications for anti-collision purposes of land vehicles

Abstract

A system for self-seeding a bidirectional mode-locked laser includes a variable retroreflector optically coupled to an output port of the laser. In a first operating state, the variable retroreflector retroreflects output light from the output port back into the output port. In a second operating state, the variable retroreflector does not retroreflect the output light. To use the system, the laser is unidirectionally mode-locked to generate a first pulse train that exits the laser via a first output port. The variable retroreflector, in the first operating state, retroreflects output light from a second output port of the laser back into the laser to initiate bidirectional mode-locking. When the laser transitions to bidirectional mode-locking, this output light becomes a second pulse train. The variable retroreflector is then transitioned to the second operating state such that the second pulse train can be used for the application at hand.

IPC Classes  ?

• H01S 3/1112 - Passive mode locking
• H01S 3/067 - Fibre lasers
• H01S 3/094 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light
• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• H01S 3/102 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling the active medium, e.g. by controlling the processes or apparatus for excitation
• H01S 3/105 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling the mutual position or the reflecting properties of the reflectors of the cavity
• H01S 3/16 - Solid materials

Abstract

Compounds and compositions useful in methods of treating genitourinary syndrome of menopause (GSM). These compounds, and compositions containing these compounds, may be used as an alternative to systemic hormonal therapies or to localized therapies using estradiol or other forms of steroidal estrogens.

IPC Classes  ?

• C07D 311/32 - 2, 3-Dihydro derivatives, e.g. flavanones
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina

Abstract

A microsurgical device and methods of its use can be used for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. A dual-blade device can be used for cutting the trabecular meshwork (“TM”) in the eye. The device tip provides entry into the Schlemm's canal via its size (i.e., for example, 0.2-0.3 mm width) and configuration where a ramp elevates the TM away from the outer wall of the Schlemm's canal and guides the TM to first and second lateral elements for creating first and second incisions through the TM. The dimensions and configuration of the blade is such that an entire strip of TM is removed without leaving TM leaflets behind and without causing collateral damage to adjacent tissues.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• A61B 17/32 - Surgical cutting instruments
• A61B 17/3211 - Surgical scalpels or knivesAccessories therefor

Abstract

This invention is related to the field of biosensors. In particular, devices and methods are described which enable the quantification of biomolecules by virtue of particle speed driven by induced-charge electrophoresis. For example, a range of biomolecules can be simultaneously detected in a highly sensitive manner from a library (e.g., combination) of active particles having different shapes or fluorescent signatures. Such biomolecules are related to conditions including, but not limited to, cancer biomarkers, viral infection biomarkers, toxins, pesticides, and small molecule drugs.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• B81B 7/00 - Microstructural systems
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

Biomarkers to predict progression from at-risk of developing rheumatoid arthritis (pre-RA) to physician-confirmed rheumatoid arthritis (i.e., Clinical RA) within defined time periods are described. The described biomarkers can be used to identify interventions to prevent, delay, or modulate future Clinical RA and to identify potential stage-specific targets for preventive interventions.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

cLcMUcMcc+0MΦ+-0MΦ-Φ+Φ−Φ00 equal 180º. The optical carrier, lower-sideband optical component, and upper-sideband optical component have the same optical spatial mode.

IPC Classes  ?

• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• G01J 3/433 - Modulation spectrometryDerivative spectrometry

Abstract

Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 2/16 - Intraocular lenses
• A61F 9/007 - Methods or devices for eye surgery

Abstract

Intraocular lenses (IOLs) that improve lens stability by, for example, increasing anterior-posterior stiffness of the IOL, increasing anterior-posterior dimensions of the IOL and/or increasing contact area with the equator of the bag to resist movement of the IOL as the bag collapses over time. These IOLs may be non-modular (single component) or modular (multiple component). In modular embodiments, the IOL system may include intraocular base and optic components, which, when combined, form a modular IOL.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A superconducting circuit for detecting single photons includes a detector sub-circuit having a superconducting branch and a bypass branch in parallel with the superconducting branch. The superconducting branch includes a superconducting nanowire single-photon detector (SNSPD). The detector sub-circuit outputs a photon-indicating signal in response to the SNSPD absorbing a single photon. The superconducting circuit also includes a fluxon generator coupled to the bypass branch of the detector sub-circuit. The fluxon generator generates one or more singleflux quantum (SFQ) pulses in response to receiving the photon-indicating signal. The superconducting circuit also includes an integrator loop that includes the fluxon generator. The integrator loop increments an integrator current flowing through the integrator loop by an incremental current for each of the one or more SFQ pulses generated by the fluxon generator. The superconducting circuit also includes a readout sub-circuit that generates an output voltage that is based on the integrator current.

IPC Classes  ?

• G01J 1/44 - Electric circuits
• G01J 11/00 - Measuring the characteristics of individual optical pulses or of optical pulse trains
• H10N 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

The present disclosure provides energy absorbing materials and methods of fabricating the same. The energy absorbing materials of the present disclosure comprise a plurality of repeating cells, wherein each of the plurality of cells comprises a three-dimensional plate lattice, wherein a least a portion of plate lattice is prebuckled.

IPC Classes  ?

• B32B 3/12 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a layer of regularly-arranged cells whether integral or formed individually or by conjunction of separate strips, e.g. honeycomb structure
• B32B 3/02 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions
• B32B 3/26 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• B32B 27/06 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• G06F 30/20 - Design optimisation, verification or simulation
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 80/00 - Products made by additive manufacturing

Abstract

A highly sensitive technology enabling selective recognition of aflatoxins such as in contaminated cereal samples. Methods for the synthesis of AgNP-containing MIP membranes from the monomer mixtures containing both methacrylate monomers and oligomers as well as AgNOs solution in dimethylformamide enable the detection system. The AgNP were formed in the structure of the polymeric membranes during the pre-heating step followed by the UV-initiated polymerization. The highly selective sensor elements where MIP membranes are combined with the Ag nanostructures as signal amplifiers (LSPR-MIP nanochips) can be stored separately and used with a simple optical recognition system as selective elements of point-of-care sensor devices, even in in-field conditions. Composite plasmonic membranes provide both highly selective recognition of the target toxin and the generation of an enhanced optical signal, allowing aflatoxin B1 detection at ultralow concentrations.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The disclosure includes a method of inhibiting a eukaryotic translation initiation factor 3e (eIF3e) comprising contacting the eIF3e with a compound or salt of the Formula I, where the variables, e.g., Y, Z, R, and R1R11 are defined herein. The disclosure includes a method of modulating SIX1 and/or EYA2 levels or inhibiting SIX1/EYA2 interactions comprising contacting eukaryotic translation initiation factor 3e (eIF3e) with a compound of the formula. The disclosure includes a method of treating metastatic breast cancer (of all subtypes), glioblastoma, Wilms' tumor, ovarian cancer, lung cancer, cervical, oral cancer, or any cancer shown to be dependent on SIX1 or EYA proteins, which are regulated by eIF3e, in a patient comprising administering the patient a compound of the Formula I.

IPC Classes  ?

• C07D 295/26 - Sulfur atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present disclosure relates generally to compositions and methods of enhancing potency of immune cell therapies by Runx2 modulation.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens

Abstract

A system for collecting and storing biological samples for analysis of NADome degradation and quantitation of NADome molecules present in the biological sample that includes a NADome sample tube, a NADome sample storage medium, and a method of preparing a sample storage medium useful in storing a biological sample for analysis of NADome degradation and quantitation of NADome molecules present in cold storage for up to 3 months prior to analysis.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 30/06 - Preparation
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The present discloses systems and methods for tissue analysis, biopsy, and treatment utilizing at least exogenous fluorophores and near infrared light. A method is disclosed for optically determining the presence of abnormal cells, such as cancer, in tissue. The method includes applying one or more exogenous fluorophores into tissue in an animal body, wherein the exogenous fluorophores include a targeting moiety formulated to bond with a selected site on abnormal cells. The method includes illuminating the one or more exogenous fluorophores in the tissue with near infrared light from an elongated optical probe to generate fluorescent light from exogenous fluorophores present in the tissue. The method includes receiving fluorescent light generated from the one or more exogenous fluorophores in the tissue. The method includes determining if abnormal cells are present in the tissue based on the fluorescent light generated from the one or more exogenous fluorophores in the tissue.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Small molecule CXC chemokine receptor type 4 (CXCR4) agonists are disclosed, methods of their manufacture, and uses thereof, in particular to improve healing and reduce the risk of injury for wound healing in diabetes.

IPC Classes  ?

• C07D 513/04 - Ortho-condensed systems
• A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

A method of stimulating dentin generation includes applying a polymerizable composition to exposed dental pulp in a dentate mammal or a dentate non-mammalian vertebrate; wherein the polymerizable composition comprises a hydroxy-substituted azobenzene group having the structure A method of stimulating dentin generation includes applying a polymerizable composition to exposed dental pulp in a dentate mammal or a dentate non-mammalian vertebrate; wherein the polymerizable composition comprises a hydroxy-substituted azobenzene group having the structure A method of stimulating dentin generation includes applying a polymerizable composition to exposed dental pulp in a dentate mammal or a dentate non-mammalian vertebrate; wherein the polymerizable composition comprises a hydroxy-substituted azobenzene group having the structure wherein x, R1, R2, R4, R5, R6, R7, R8, R9, and R10 are defined herein; and polymerizing the polymerizable composition; wherein the amount of the hydroxy-substituted azobenzene group applied to the exposed dental pulp is effective to promote dentin generation.

IPC Classes  ?

• A61K 6/887 - Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61K 6/52 - CleaningDisinfecting
• A61K 6/71 - Fillers

Abstract

The present disclosure provides a high-performance integrated strain sensing device that is highly stretchable, rehealable, recyclable and reconfigurable. This device can include dynamic covalent thermoset polyimine as the substrate and encapsulation, eutectic liquid metal alloy as the strain sensing unit and interconnects, and off-the-shelf chip components for measuring and magnifying functions. The device can be attached on the knee, elbow, wrist and finger joints for strain sensing and motion monitoring, and can also be attached on the abdomen to accurately measure respiration cycles.

IPC Classes  ?

• G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01L 1/20 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress

Abstract

The present invention relates to the field of immunology. More specifically, the present invention provides methods and compositions directed to the use of antibodies to the pancreatic zinc transporter, ZnT8. In particular embodiments, the anti-ZnT8 antibodies specifically bind the transmembrane domain of ZnT8. In more specific embodiments, the anti-ZnT8 antibodies specifically the extracellular surface of the transmembrane domain.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof

Abstract

An implantable anastomotic assembly, which is configured to be attached to cardiovascular tissue, includes a connection interface, a plurality of outer plates, and a plurality of connectors configured to extend between and interconnect the connection interface and the plurality of outer plates, respectively, according to various embodiments. The connection interface is separate from and non-contiguous with the plurality of outer plates, according to various embodiments.

IPC Classes  ?

• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
• A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
• A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
• A61M 60/863 - Apex rings

Abstract

A method and apparatus for connecting a first medical data repository to a first node, the first node configured to obtain a set of medical data from the first medical data repository and refine the set of the medical data, refining, based on one or more parameters, the set of medical data to produce a set of refined medical data; and outputting the set of the refined medical data, the set of the refined medical data configured for seamless integration with a second medical data repository.

IPC Classes  ?

• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

A pharmaceutical combination having one or more MDM2 inhibitor and one or more inhibitor of dephosphorylation of elF2α. MDM2 inhibitors are non-peptide small molecule inhibitors or stapled peptide inhibitors of the interaction between MDM2 and p53. Inhibitors of phosphorylation of elF2α are non-peptide small molecule inhibitors. Components of the pharmaceutical combination are administered to a subject in need thereof in a combined therapeutic amount to provide therapeutic effect and optionally synergistic therapeutic effect. A method for treatment of proliferative disease or disorders, including various cancers, which comprises administering to a subject in need thereof of one or more MDM2 inhibitor and one or more inhibitor of dephosphorylation of elF2α, wherein the inhibitors are administered in a combined therapeutic amount to provide therapeutic effect and optionally synergistic therapeutic effect.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 35/00 - Antineoplastic agents

Abstract

Embodiments disclosed herein relate to an endoscopic device and a method to provide dynamic visualization of the middle ear. The endoscopic device includes a handle and a shaft extending therefrom. The shaft includes a rigid portion distal the handle and an articulating portion distal the rigid portion. The articulating portion is configured to articulate with respect to the rigid portion. The articulating portion includes an imaging sensor coupled thereto. The handle can include one or more actuators configured to cause the articulating portion to articulate.

IPC Classes  ?

• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61B 1/008 - Articulations
• A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion

Abstract

A re-configurable intelligent surface system, RIS, sometimes also referred to as reflective intelligent surface or large intelligent surface, is disclosed. The RIS includes an array (210) of multiple elements (320, 321, 322, 323) and interconnections (721, 722, 723) in between at least some of its elements (320, 321, 322, 323).

IPC Classes  ?

• H04B 7/04 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas
• H01Q 3/28 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the amplitude
• H01Q 3/46 - Active lenses or reflecting arrays
• H01Q 21/06 - Arrays of individually energised antenna units similarly polarised and spaced apart
• H01Q 15/14 - Reflecting surfacesEquivalent structures
• H04B 7/155 - Ground-based stations
• H04B 7/145 - Passive relay systems

Abstract

Disclosed are cellulose-based flexible gels containing cellulose nanorods, ribbons, fibers, and the like, and cellulose-enabled inorganic or polymeric composites, wherein the gels have tunable optical, heat transfer, and stiffness properties. The disclosed gels are in the form of hydrogels, organogels, liquid-crystal (LC) gels, and aerogels, depending on the solvents in the gels.

IPC Classes  ?

• C08J 9/35 - Composite foams, i.e. continuous macromolecular foams containing discontinuous cellular particles or fragments
• C08J 9/00 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• C09K 5/14 - Solid materials, e.g. powdery or granular

Abstract

A solid-state battery includes an anode material including silicon or tin. The anode material may include silicon and/or tin in various forms including layers or intermixed particles of various phases and crystallinity.

IPC Classes  ?

• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 10/0562 - Solid materials
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type

Abstract

The present disclosure provides a method for continuous, simultaneous control over mechanical properties of composite materials realized using additive manufacturing. In one aspect, various composites additively manufactured using the combination of a rigid plastic, a soft elastomer, and a liquid were empirically characterized, demonstrating materials which span four orders of magnitude in modulus and two orders of magnitude in toughness.

IPC Classes  ?

• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present invention is directed to a method for inhibiting the self-cleavage of PEG10 for treatment of ALS comprising the step of administering to a subject a therapeutically effective amount of ritonavir.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings

Abstract

A method for spectroscopic gas sensing processes a measured spectrum generated by an optical spectrometer. The method includes transforming, with a locality-sensitive hash function, the measured spectrum into an integer hash value h. The method also includes adding, to a candidate set of candidate spectra, template spectra stored in an hth bin of a look-up table. The method also includes calculating, based on each candidate spectrum in the candidate set, a measure that quantifies discrepancy between the measured spectrum and said each candidate spectrum. The method also includes identifying, based on the measure, a best-match spectrum of the candidate spectra, and retrieving, from the hth bin of the look-up table, a parameter set corresponding to the best-match spectrum. The method also includes deriving, based on the parameter set, one or more properties of the gas sample.

IPC Classes  ?

• G01N 21/39 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using tunable lasers
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

Methods and systems for the preparation of high purity and high quality cannabinoid acids and metal salts of cannabinoids. Cannabidiolic acid (CBDA) is a major cannabinoid of interest for and health reasons. It is the natural precursor of cannabidiol (CBD). The invention provides methods for the synthesis of CBDA from CBD with reagents that produce a high purity product without need for further purification. Insertion of a magnesium complexing agent prior to conversion of the reaction intermediate to the final acid product produces a high purity product with aesthetically pleasing white color and neutral odor. Methods are provided for the simultaneous synthesis and purification of cannabinoid acids, especially CBDA, produced from high purity CBD (or other cannabinoid) via a Kolbe-Schmitt type reaction using an organic base, such as DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), incorporating complexation of acid anions to a multivalent metal, alkaline earth or transition metal, prior to product acid work-up. During the work-up to the final acid, the distinct solubility of the complex in selected solvents is used advantageously to first exclude water soluble reagents and impurities and next to exclude lipophilic hydroxyl-quinone impurities, as well as any unconverted CBD.

IPC Classes  ?

• C07C 51/573 - SeparationPurificationStabilisationUse of additives

Abstract

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a first CAR that binds to a first antigen and a second CAR comprising a LAT intracellular signaling domain that binds to a second antigen, and methods of use in treating cancers, such as solid tumors and hematological malignancies.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A method for characterizing gas emissions includes measuring first and second optical beams to generate first and second absorption signals, respectively. Each of the optical beams is transmitted from a center point and retroreflected back to the center point. Paths of the optical beams define boundaries of a sector. Based on the absorption signals, an emission rate of a gas from within the sector is determined. If the emission rate exceeds a threshold, a third optical beam is measured to generate a third absorption signal. The third optical beam is transmitted from the center point and retroreflected back to the center point. The third optical beam propagates along a path that divides the sector into first and second subsectors. Based on the first, second, and third absorption signals, a location of a source of the gas is identified as being within the first subsector or the second subsector.

IPC Classes  ?

• G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry
• G01M 3/38 - Investigating fluid tightness of structures by using light
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01V 8/22 - Detecting, e.g. by using light barriers using multiple transmitters or receivers using reflectors

Abstract

A microporous crystalline lattice composition formed by a plurality of chemical subunits bound by a series of cross-linked covalent tetraphenoxyb orate linkages and weak ion-dipole interactions forming an ionic covalent organic framework (ICOF) having a plurality of tunable iso-surface channels.

IPC Classes  ?

• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties

Abstract

Devices including nematic liquid crystal-forming molecules are disclosed. The molecules include one or more dipoles and exist in a ferroelectric nematic state. Exemplary devices can further include an electrode for applying an electric field in, for example, and in-plane direction.

IPC Classes  ?

• G02F 1/141 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering based on orientation effects in which the liquid crystal remains transparent using ferroelectric liquid crystals
• G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G02F 1/135 - Liquid crystal cells structurally associated with a photoconducting or a ferro-electric layer, the properties of which can be optically or electrically varied
• G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

The present disclosure provides a combination engineered cell therapy comprising pluripotent stem cell-derived cells engineered to express an inert cell surface protein and regulatory T cells engineered to express a chimeric antigen receptor specific for said cell surface protein. Further provided are methods of treating a disease, such as type 1 diabetes, by administering said combination engineered cell therapy.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61L 27/38 - Animal cells
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

6543744), and the solvent is an ether-based solvent.

IPC Classes  ?

• H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
• H01G 11/60 - Liquid electrolytes characterised by the solvent
• C07F 5/02 - Boron compounds
• H01M 6/16 - Cells with non-aqueous electrolyte with organic electrolyte
• H01G 11/64 - Liquid electrolytes characterised by additives

Abstract

Random co-polymer brushes with aromatic monomer ethylene glycol phenyl ether methacrylate (EGPMA) and zwitterionic sulfobetaine methacrylate (SBMA) to stabilize enzymes that are immobilized to the brush layer. It is shown herein that that the incorporation of 5% EGPMA results in the dramatic stabilization of immobilized lipase, which resulted in a 50°C increase in the enzyme's temperature optimum. By stabilizing the enzyme at elevated temperatures, a 50-fold increase in catalytic activity was observed relative to the unmodified enzyme. Importantly, the incorporation of EGPMA enables new types of interactions with the enzyme compared to prior brush surfaces that contribute to this stabilizing effect.

IPC Classes  ?

• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08J 7/16 - Chemical modification with polymerisable compounds
• C08L 23/06 - Polyethene
• C08L 27/06 - Homopolymers or copolymers of vinyl chloride

Abstract

Systems, methods, and processes for predicting and validating one or more previously unknowing growth conditions for a microorganism which can allow for the culturing of previously unculturable microorganisms, or can identify optimal grown conditions for a known or unknown microorganism.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/20 - Supervised data analysis
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12N 1/20 - BacteriaCulture media therefor
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Abstract

Described herein are compositions and methods useful in treating endothelial cells of the retina in a patient suffering from or at risk developing a condition related to retinal deterioration. In some embodiments, the condition may be diabetes, diabetic retinopathy, or ischemia/reperfusion injury. In some embodiments, the endothelial cells may be capillary' cells. In many embodiments, the composition and methods may result in increased expression of DJ-1 in the endothelial cells.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/864 - Parvoviral vectors

Abstract

Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• C07K 14/81 - Protease inhibitors
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

A tunable microwave circulator has first, second, and third branches, each branch including a coupler, an amplifier, and a variable impedance circuit. Each coupler has an input port, a coupled port, a transmitted port, and an isolated port. In each branch, an input of the amplifier connects to the transmitted port and the variable impedance circuit connects to the isolated port. An output of the amplifier of the first branch connects to the coupled port of the coupler of the second branch, an output of the amplifier of the second branch connects to the coupled port of the coupler of the third branch, and the output of the amplifier of the third branch connects to the coupled port of the coupler of the first branch. Each variable impedance circuit may be adjusted to reduce mismatched impedance at the corresponding input ports.

IPC Classes  ?

• H01P 1/38 - Circulators
• H01P 5/04 - Coupling devices of the waveguide type with variable factor of coupling
• H01P 5/12 - Coupling devices having more than two ports
• H03F 1/56 - Modifications of input or output impedances, not otherwise provided for

Abstract

A vascular access device and assembly characterized by a tubular access graft having at least one angled distal flange that forms a non-circular distal opening to the tubular access graft, with the angled distal flange having a reinforcement structure that expands the flange and abuts a luminal wall surface of a blood vessel.

IPC Classes  ?

• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis

Abstract

A novel bioreactor to efficiently expand cells in space. A two-chamber system where the chambers are separated by a porous membrane that retains the cells in one chamber but permits nutrients and wastes to pass through freely between chambers. Media can be exchanged in the non-cell chamber without disturbing the cells in the cell chamber or subjecting them to fluid shear. The culture cassette includes a larger cell chamber, no sharp corners to prevent dead spaces, fittings to inject and manipulate fluids through the chambers without the need for needles. The cell chamber has been outfitted with a thin plastic film that permits gas exchange. The two-chamber system can be mounted into a tray that includes a fluidic loop to circulate fresh media through the non-cell chamber using a dedicated peristaltic pump. To monitor the cell expansion cycle, pH and OD sensors are integrated into each bioreactor tray.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 3/04 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present disclosure relates to a method that includes reacting a mixture that includes a carrier gas and a precursor to form a first solid product and heating the first solid product to a temperature between 500 C and 1000 C to form a second solid product, where the precursor is a vapor, the reacting is performed using a plasma energized using a radio frequency (RF), the reacting is performed at an absolute pressure between 0.8 atms and 1.2 atms, the first solid product includes nickel and lithium, and the second solid product includes nickel, manganese, cobalt, lithium, and oxygen.

IPC Classes  ?

• C01D 15/00 - Lithium compounds
• C01G 53/00 - Compounds of nickel
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

Abstract

The present invention includes light-controlled and light-independent neurotoxin systems and methods for using such neurotoxin systems for rapidly and locally silencing distinct populations of neurons.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 9/52 - Proteinases derived from bacteria
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Embodiments of the instant disclosure relate to compositions and methods for generating and using humanized mice including, but not limited to, stem-cell derived thymic organoids (sTOs). In certain embodiments, a humanized mouse can be developed where T cells can be educated in a patient-derived sTO autologous to the patient providing a reliable, reproducible, and complete environment to study disorder-related immunity and patient-specific immunity. In certain embodiments, the subject has cancer, an autoimmune disorder, an immunocompromising disorder, or other disorder. In other embodiments, therapeutic agents can be assessed for efficacy to treat, for example, disorder-related immunity, cancer, and patient specific immunity using the humanized mouse.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/09 - Recombinant DNA-technology
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes

Abstract

22S, siloxanes and volatile organic compounds (VOCs) in a way that leverages humidity management and ferromagnetic separation with sequential slag filtration columns.

IPC Classes  ?

• C21B 13/00 - Making spongy iron or liquid steel, by direct processes
• C21B 11/00 - Making pig-iron other than in blast furnaces
• C21B 7/00 - Blast furnaces

Abstract

A system for validating statistical information using name-entity recognition is configurable to: generate a set of embeddings based on a set of input text using an embedding layer of a statistical extraction model; generate a set of contextual features by processing the set of embeddings using a recurrent layer of the statistical extraction model; generate a label sequence for the set of input text using a structured prediction layer of the statistical extraction model, wherein the label sequence indicates statistical information present in the set of input text, wherein the statistical information includes a reported statistical result; reconstruct a statistical test using at least part of the statistical information, wherein the statistical test provides a computed statistical result for comparison with the reported statistical result; and generate a consistency label for the reported statistical result based on a comparison of the computed statistical result with the reported statistical result.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G06F 18/21 - Design or setup of recognition systems or techniquesExtraction of features in feature spaceBlind source separation
• G06F 18/241 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

The present disclosure provides a compound of the formula Ar1-L1-Ar2-S-(L2mm-Ar3(I), wherein m is 0 or 1; Ar1is aryl or heteroaryl each of which is optionally substituted; L1is a first linker selected from the group consisting of (II), III and (IV); Ar2is arylene or heteroarylene each of which is optionally substituted; L2is alkylene; Ar3is aryl or heteroaryl each of which is optionally substituted or -NR1R2; each X1is O, NR1, or S; each X2is O, NR2, or S; each of Y is independently H or halide; and each of R1, R2, and Ra is independently H, alkyl, or a nitrogen protecting group, provided when Ar2is furylene or optionally substituted phenylene, then L1 is not -C(=O)-NH-N=CH- The present disclosure also provides methods for using compound of Formula I in treating a clinical condition associated with EYA2 tyrosine phosphatase activity.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/33 - Heterocyclic compounds

Abstract

Methods and devices for magnetic resonance imaging (MRI) and, more particularly, to a method and apparatus that is able to apply a mechanical load to the human knee in vivo within an MRI environment, and when combined with inverse constitutive modeling, enables the measurement of cartilage structure and mechanical function.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

A device includes a first reflector composed of a first reflector material that is electrically conductive, a second reflector facing the first reflector to form an optical cavity, and an electrode located between the first reflector and the second reflector. The electrode is composed of an electrode material that is both electrically conductive and at least partially transparent. Examples of the electrode material include metal, transparent conductive oxides, semiconductors, and conductive polymers. To harvest energy, a current driven through the device creates a stream of charge carriers that flows between the first reflector and the electrode. The second reflector may also be composed of an electrically conductive material, in which case a second current may be driven through the device to create a second stream of charge carriers that flows between the second reflector and the electrode.

IPC Classes  ?

• H02N 11/00 - Generators or motors not provided for elsewhereAlleged perpetua mobilia obtained by electric or magnetic means
• H10N 10/10 - Thermoelectric devices comprising a junction of dissimilar materials, i.e. devices exhibiting Seebeck or Peltier effects operating with only the Peltier or Seebeck effects

Abstract

In various implementations, technology is disclosed to dynamically assess airway deformation. A depth prediction model is used to estimate airway depth from monocular endoscopic images of an airway and to create a dynamic point cloud representation of the airway. The depth prediction model is trained using synthetic image and depth data derived from a 3D airway model. The dynamic point cloud representation of the airway can be used to visualize and quantify airway contours and to classify airway obstructions and behavior. The technology described provides objective measures of airway deformations and behavioral analysis of pulmonary related conditions.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• G06T 7/50 - Depth or shape recovery

Abstract

MycobacteriumMycobacterium species designated MTC 0012 (PTA-127651) and its anti-inflammatory, immunoregulatory, and stress resilience effects in subjects in need thereof. The present invention describes the use of MTC 0012 for the treatment and/or prophylactic prevention of trauma- and stressor-related disorders, such as PTSD.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 35/74 - Bacteria
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present disclosure generally relates to compositions and methods that involve the use Enantiomer-Testosterone (Ent-Testosterone). The disclosed Ent-Testosterone can be used to inhibit quorum sensing in bacteria. The disclosure further compositions and method for treating a subject with bacterial infection or a condition complicated by colonization of bacteria.

IPC Classes  ?

• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/04 - Antibacterial agents
• C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane